Innovation Pharmaceuticals Inc (IPIX) Fair Value & Analysis
Healthcare · US · Market cap $156K
Innovation Pharmaceuticals Inc
IPIX · US
Fair value as of: Jun 26, 2026
From 2 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0200 to $0.0003 (−98.5%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0060 · the $0.0003 price screens below the $0.0003 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Innovation Pharmaceuticals Inc (IPIX) currently trades at $0.0003, while our model-based Fair Value estimate is $0.0003 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $18.0K. The balance sheet holds a net cash position of $1.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Innovation Pharmaceuticals Inc reported revenue of $18.0K in FY2023 versus $0 in FY2019. Reported net income was −$3.2M in FY2023.
Is IPIX fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Innovation Pharmaceuticals Inc (IPIX) undervalued?
What is the fair value of IPIX?
What is the quality score of IPIX?
What is the revenue of Innovation Pharmaceuticals Inc (IPIX)?
What is the net profit margin of IPIX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.